Development of microbiome-based Precision Medicine tool for optimal immune-oncology treatment

Offentlig prosjektsammendrag

Bio-Me launched its breakthrough Precision Microbiome Profiling (PMP™) technology last year and will now further develop it into a series of tools that can assist oncologists to significantly improve the proportion of responders to promising new cancer treatments, called immune checkpoint inhibitors (ICI). PMP™ can rapidly and accurately profile gut bacteria known to interfere with the action of cancer drugs. Bio-Me will join forces with leading medical specialists and researchers to tackle cancer treatment response rate problems by developing diagnostic tests set to drastically improve patient outcomes. These tests could become widely available soon after the project is completed at the end of 2023.